

Scott M Grundy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8596839/publications.pdf>

Version: 2024-02-01

213
papers

106,533
citations

2091

103
h-index

1801

217
g-index

230
all docs

230
docs citations

230
times ranked

76555
citing authors

#	ARTICLE	IF	CITATIONS
1	Harmonizing the Metabolic Syndrome. <i>Circulation</i> , 2009, 120, 1640-1645.	1.6	11,462
2	Diagnosis and Management of the Metabolic Syndrome. <i>Circulation</i> , 2005, 112, 2735-2752.	1.6	9,757
3	Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). <i>Circulation</i> , 2001, 103, 1859-1882.	1.6	8,314
4	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Circulation</i> , 2004, 110, 227-239.	1.6	5,602
5	The metabolic syndrome. <i>Lancet</i> , 2005, 365, 1415-1428.	6.3	5,212
6	Definition of Metabolic Syndrome. <i>Circulation</i> , 2004, 109, 433-438.	1.6	4,617
7	Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2982-3021.	1.2	4,468
8	Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. <i>Hepatology</i> , 2004, 40, 1387-1395.	3.6	3,250
9	Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2005, 352, 1425-1435.	13.9	3,152
10	The metabolic syndrome. <i>Lancet</i> , 2010, 375, 181-183.	6.3	2,488
11	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1082-e1143.	1.6	2,380
12	Diabetes and Cardiovascular Disease. <i>Circulation</i> , 1999, 100, 1134-1146.	1.6	1,903
13	Validation of the Framingham Coronary Heart Disease Prediction Scores. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 180.	3.8	1,798
14	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. <i>Circulation</i> , 2006, 113, 2363-2372.	1.6	1,742
15	AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. <i>Circulation</i> , 2002, 106, 388-391.	1.6	1,623
16	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, e285-e350.	1.2	1,550
17	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. <i>Circulation</i> , 2011, 124, 2458-2473.	1.6	1,369
18	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Journal of the American College of Cardiology</i> , 2004, 44, 720-732.	1.2	1,207

#	ARTICLE	IF	CITATIONS
19	Metabolic Syndrome Pandemic. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 629-636.	1.1	1,202
20	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3168-3209.	1.2	1,128
21	Obesity, Metabolic Syndrome, and Cardiovascular Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2595-2600.	1.8	1,056
22	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1289.	3.8	974
23	ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring By Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain. <i>Journal of the American College of Cardiology</i> , 2007, 49, 378-402.	1.2	891
24	Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels. <i>Mayo Clinic Proceedings</i> , 2003, 78, 965-978.	1.4	855
25	HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia. <i>New England Journal of Medicine</i> , 1988, 319, 24-33.	13.9	762
26	Comparison of Monounsaturated Fatty Acids and Carbohydrates for Lowering Plasma Cholesterol. <i>New England Journal of Medicine</i> , 1986, 314, 745-748.	13.9	716
27	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2432-2446.	1.2	700
28	American College of Cardiology/American Heart Association Expert Consensus Document on Electron-Beam Computed Tomography for the Diagnosis and Prognosis of Coronary Artery Disease. <i>Circulation</i> , 2000, 102, 126-140.	1.6	664
29	ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. <i>Circulation</i> , 2002, 106, 1024-1028.	1.6	657
30	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€”Full Report. <i>Journal of Clinical Lipidology</i> , 2015, 9, 129-169.	0.6	632
31	Definition of Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, e13-8.	1.1	627
32	Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk?. <i>Circulation</i> , 2004, 109, 2818-2825.	1.6	578
33	Metabolic syndrome update. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 364-373.	2.3	576
34	Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 399-404.	1.8	566
35	AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update. <i>Circulation</i> , 2001, 104, 1577-1579.	1.6	564
36	Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A consensus statement from the American Heart Association and American Diabetes Association. <i>Diabetes Care</i> , 2004, 27, 256-263.	4.3	561

#	ARTICLE	IF	CITATIONS
37	ACC/AHA/NHLBI clinical advisory on the use and safety of statins ¹ When citing this document, the American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute would appreciate the following citation format: Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the Use and Safety of Statins. J Am Coll Cardiol 2002;40:568-73.22 This document is available on the Web sites of the ACC (www.acc.org), the		



#	ARTICLE	IF	CITATIONS
55	Diagnosis and Management of the Metabolic Syndrome. <i>Circulation</i> , 2005, 112, .	1.6	332
56	Plant sterols as cholesterol-lowering agents: Clinical trials in patients with hypercholesterolemia and studies of sterol balance. <i>Atherosclerosis</i> , 1977, 28, 325-338.	0.4	326
57	AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1581-1583.	1.2	319
58	Ethnic differences in hepatic steatosis: An insulin resistance paradox?. <i>Hepatology</i> , 2009, 49, 791-801.	3.6	309
59	Obesity, Metabolic Syndrome, and Coronary Atherosclerosis. <i>Circulation</i> , 2002, 105, 2696-2698.	1.6	303
60	Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. <i>Journal of Lipid Research</i> , 1972, 13, 531-551.	2.0	293
61	Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI) Tj ETQq1 1 0,784314 r gBT /Ovrd 0.7 290	0.7	290
62	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	0.6	289
63	Small LDL, Atherogenic Dyslipidemia, and the Metabolic Syndrome. <i>Circulation</i> , 1997, 95, 1-4.	1.6	288
64	Influence of Body Fat Content and Distribution on Variation in Metabolic Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4459-4466.	1.8	270
65	Approach to lipoprotein management in 2001 National Cholesterol Guidelines. <i>American Journal of Cardiology</i> , 2002, 90, 11-21.	0.7	267
66	Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy. <i>Circulation</i> , 2002, 106, 2526-2529.	1.6	259
67	Transport of Very Low Density Lipoprotein Triglycerides in Varying Degrees of Obesity and Hypertriglyceridemia. <i>Journal of Clinical Investigation</i> , 1979, 63, 1274-1283.	3.9	257
68	Cholesterol and Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 1986, 256, 2849.	3.8	254
69	Joint Distribution of Non-HDL and LDL Cholesterol and Coronary Heart Disease Risk Prediction Among Individuals With and Without Diabetes. <i>Diabetes Care</i> , 2005, 28, 1916-1921.	4.3	246
70	Non-High-Density Lipoprotein and Very-Low-Density Lipoprotein Cholesterol and Their Risk Predictive Values in Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2006, 98, 1363-1368.	0.7	245
71	Dietary β -sitosterol as an internal standard to correct for cholesterol losses in sterol balance studies. <i>Journal of Lipid Research</i> , 1968, 9, 374-387.	2.0	243
72	A Physiological Method for Estimation of Hepatic Secretion of Biliary Lipids in Man. <i>Gastroenterology</i> , 1972, 62, 1200-1217.	0.6	236

#	ARTICLE	IF	CITATIONS
73	Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 295-309.	21.5	230
74	Chylomicron clearance in normal and hyperlipidemic man. <i>Metabolism: Clinical and Experimental</i> , 1976, 25, 1225-1239.	1.5	221
75	The CardioMetabolic Health Alliance. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1050-1067.	1.2	211
76	Primary Prevention of Coronary Heart Disease. <i>Circulation</i> , 1999, 100, 988-998.	1.6	204
77	Insulin Resistance and Body Fat Distribution in South Asian Men Compared to Caucasian Men. <i>PLoS ONE</i> , 2007, 2, e812.	1.1	190
78	Statin Trials and Goals of Cholesterol-Lowering Therapy. <i>Circulation</i> , 1998, 97, 1436-1439.	1.6	187
79	Fibric acids: Effects on lipids and lipoprotein metabolism. <i>American Journal of Medicine</i> , 1987, 83, 9-20.	0.6	186
80	Relationship Between C-Reactive Protein and Subclinical Atherosclerosis. <i>Circulation</i> , 2006, 113, 38-43.	1.6	184
81	Relationship of Anterior and Posterior Subcutaneous Abdominal Fat to Insulin Sensitivity in Nondiabetic Men. <i>Obesity</i> , 1997, 5, 93-99.	4.0	178
82	Metabolic Complications of Obesity. <i>Endocrine</i> , 2000, 13, 155-165.	2.2	174
83	African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1011-1017.	1.2	171
84	No Association Between Plasma Levels of Plant Sterols and Atherosclerosis in Mice and Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2326-2332.	1.1	167
85	Adipose Tissue Metabolites and Insulin Resistance in Nondiabetic Asian Indian Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2750-2755.	1.8	165
86	Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. <i>American Journal of Cardiology</i> , 2003, 91, 956-960.	0.7	163
87	The Association of Differing Measures of Overweight and Obesity With Prevalent Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2007, 50, 752-759.	1.2	156
88	Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 2315-2325.	1.6	154
89	Does the Metabolic Syndrome Exist?. <i>Diabetes Care</i> , 2006, 29, 1689-1692.	4.3	151
90	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2013, 7, 561-565.	0.6	147

#	ARTICLE	IF	CITATIONS
91	Does a diagnosis of metabolic syndrome have value in clinical practice?1,2. American Journal of Clinical Nutrition, 2006, 83, 1248-1251.	2.2	146
92	Hepatic lipase activity is lower in African American men than in white American men: effects of 5â€² flanking polymorphism in the hepatic lipase gene (LIPC). Journal of Lipid Research, 1998, 39, 228-232.	2.0	139
93	Sex Differences in the Relationship between C-Reactive Protein and Body Fat. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3251-3258.	1.8	136
94	An assessment by the Statin Intolerance Panel: 2014 update. Journal of Clinical Lipidology, 2014, 8, S72-S81.	0.6	135
95	Adipose tissue and metabolic syndrome: too much, too little or neither. European Journal of Clinical Investigation, 2015, 45, 1209-1217.	1.7	129
96	Harmonizing the Definition of the Metabolic Syndrome: Comparison of the Criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European Populations. American Journal of Cardiology, 2007, 99, 541-548.	0.7	128
97	Genetic Polymorphism PC-1 K121Q and Ethnic Susceptibility to Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5927-5934.	1.8	119
98	Diet composition and the metabolic syndrome: what is the optimal fat intake?. American Journal of Medicine, 2002, 113, 25-29.	0.6	117
99	Elevated Plasma High-Sensitivity C-Reactive Protein Concentrations in Asian Indians Living in the United States. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3773-3776.	1.8	109
100	United states cholesterol guidelines 2001: expanded scope of intensive low-density lipoproteinâ€“lowering therapy. American Journal of Cardiology, 2001, 88, 23-27.	0.7	103
101	Interleukin-18, the Metabolic Syndrome, and Subclinical Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2043-2049.	1.1	99
102	Coronary plaque as a replacement for age as a risk factor in global risk assessment. American Journal of Cardiology, 2001, 88, 8-11.	0.7	88
103	The Metabolic Syndrome. Circulation, 2003, 108, 1537-1540.	1.6	87
104	The Issue of Statin Safety. Circulation, 2005, 111, 3016-3019.	1.6	87
105	Metabolic Risk Susceptibility in Men Is Partially Related to Adiponectin/Leptin Ratio. Journal of Obesity, 2013, 2013, 1-9.	1.1	85
106	Effects of sucrose polyester on cholesterol metabolism in man. Metabolism: Clinical and Experimental, 1979, 28, 994-1000.	1.5	83
107	Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: Lack of effect on low-density lipoprotein concentrations or turnover. Journal of Pediatrics, 1988, 113, 387-392.	0.9	83
108	Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clinical Cornerstone, 2006, 8, S21-S27.	1.0	81

#	ARTICLE	IF	CITATIONS
109	Metabolic correlates of nonalcoholic fatty liver in women and men. <i>Hepatology</i> , 2007, 46, 716-722.	3.6	78
110	A constellation of complications: The metabolic syndrome. <i>Clinical Cornerstone</i> , 2005, 7, 36-45.	1.0	76
111	Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. <i>Current Opinion in Lipidology</i> , 1996, 7, 209-216.	1.2	75
112	Managing Atherosclerotic Cardiovascular Risk in Young Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 819-836.	1.2	72
113	What is the contribution of obesity to the metabolic syndrome?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004, 33, 267-282.	1.2	70
114	Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 800-809.	1.8	70
115	Point: The Metabolic Syndrome Still Lives. <i>Clinical Chemistry</i> , 2005, 51, 1352-1354.	1.5	64
116	Cardiorespiratory Fitness and Metabolic Risk. <i>American Journal of Cardiology</i> , 2012, 109, 988-993.	0.7	64
117	Waist Circumference as Measure of Abdominal Fat Compartments. <i>Journal of Obesity</i> , 2013, 2013, 1-9.	1.1	64
118	Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). <i>American Journal of Cardiology</i> , 2005, 95, 194-198.	0.7	63
119	Sex differences in the association between leptin and CRP: Results from the Dallas Heart Study. <i>Atherosclerosis</i> , 2007, 195, 404-410.	0.4	62
120	Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study). <i>American Journal of Cardiology</i> , 2009, 103, 1694-1702.	0.7	62
121	Overnutrition, Ectopic Lipid and the Metabolic Syndrome. <i>Journal of Investigative Medicine</i> , 2016, 64, 1082-1086.	0.7	62
122	Cholesterol and Coronary Heart Disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1990, 50, 17-24.	0.6	61
123	Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. <i>Journal of Lipid Research</i> , 1998, 39, 1127-1130.	2.0	60
124	2013 ACC/AHA Guideline Recommends Fixed-Dose Strategies Instead of Targeted Goals to Lower Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2014, 64, 601-612.	1.2	58
125	Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 96-101.	0.9	57
126	Stanol Esters as a Component of Maximal Dietary Therapy in the National Cholesterol Education Program Adult Treatment Panel III Report. <i>American Journal of Cardiology</i> , 2005, 96, 47-50.	0.7	52

#	ARTICLE	IF	CITATIONS
127	Hepatic Lipase (LIPC) Promoter Polymorphism in Men With Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1975-1978.	1.1	51
128	Next Steps in Primary Prevention of Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1828-1836.	1.2	50
129	Accumulation of 7 β -hydroxy-4-cholesten-3-one and cholesta-4,6-dien-3-one in patients with cerebrotendinous xanthomatosis: Effect of treatment with chenodeoxycholic acid. <i>Hepatology</i> , 1987, 7, 266-271.	3.6	49
130	Promise of Low-Density Lipoproteinâ€“Lowering Therapy for Primary and Secondary Prevention. <i>Circulation</i> , 2008, 117, 569-573.	1.6	45
131	Variable Contributions of Fat Content and Distribution to Metabolic Syndrome Risk Factors. <i>Metabolic Syndrome and Related Disorders</i> , 2008, 6, 281-288.	0.5	41
132	Correlation of Nonâ€“High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin + Fenofibrate Therapy in Patients With Combined Hyperlipidemia (A Subanalysis of the SAFARI Trial). <i>American Journal of Cardiology</i> , 2009, 104, 548-553.	0.7	41
133	Can we dramatically reduce the incidence of coronary heart disease?. <i>Nature Reviews Cardiology</i> , 2011, 8, 721-725.	6.1	40
134	The possible role of the arterial microcirculation in the pathogenesis of atherosclerosis. <i>Journal of Chronic Diseases</i> , 1980, 33, 679-684.	1.3	39
135	Does Dietary Cholesterol Matter?. <i>Current Atherosclerosis Reports</i> , 2016, 18, 68.	2.0	39
136	Cardiovascular and Metabolic Risk Factors: How Can We Improve Outcomes in the High-Risk Patient?. <i>American Journal of Medicine</i> , 2007, 120, S3-S8.	0.6	38
137	Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers. <i>PLoS ONE</i> , 2014, 9, e114519.	1.1	38
138	2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterolâ€“Secondary Prevention. <i>JAMA Cardiology</i> , 2019, 4, 589.	3.0	38
139	2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline*. <i>Annals of Internal Medicine</i> , 2019, 170, 779.	2.0	38
140	Nonâ€“High-Density Lipoprotein Cholesterol Level as Potential Risk Predictor and Therapy Target. <i>Archives of Internal Medicine</i> , 2001, 161, 1379.	4.3	36
141	Metabolic Syndrome and Hyperglycemia: Congruence and Divergence. <i>American Journal of Cardiology</i> , 2006, 98, 982-985.	0.7	36
142	2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. <i>JAMA Cardiology</i> , 2019, 4, 488.	3.0	33
143	The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 375-383.	1.6	32
144	The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes. <i>Diabetes Care</i> , 2020, 43, 1673-1678.	4.3	31

#	ARTICLE	IF	CITATIONS
145	Cardiorespiratory Fitness, LDL Cholesterol, and CHD Mortality in Men. <i>Medicine and Science in Sports and Exercise</i> , 2012, 44, 2132-2137.	0.2	30
146	Effects of AOMA on cholesterol metabolism in man. <i>Metabolism: Clinical and Experimental</i> , 1982, 31, 733-739.	1.5	29
147	Comparisons of Apolipoprotein B Levels Estimated by Immunoassay, Nuclear Magnetic Resonance, Vertical Auto Profile, and Non-High-Density Lipoprotein Cholesterol in Subjects With Hypertriglyceridemia (SAFARI Trial). <i>American Journal of Cardiology</i> , 2011, 108, 40-46.	0.7	29
148	Three polymorphisms associated with low hepatic lipase activity are common in African Americans. <i>Journal of Lipid Research</i> , 1998, 39, 1900-1903.	2.0	27
149	Oxidized LDL and atherogenesis: Relation to risk factors for coronary heart disease. <i>Clinical Cardiology</i> , 1993, 16, 3-5.	0.7	23
150	Statin Therapy in Older Persons. <i>Archives of Internal Medicine</i> , 2002, 162, 1329.	4.3	22
151	Effect of Colesevelam Hydrochloride on Glycemia and Insulin Sensitivity in Men With the Metabolic Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 1129-1135.	0.7	22
152	Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome. <i>Journal of the Endocrine Society</i> , 2017, 1, 1417-1427.	0.1	22
153	Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. <i>Journal of the American College of Cardiology</i> , 2019, 74, 712-714.	1.2	21
154	Atherosclerosis Imaging and the Future of Lipid Management. <i>Circulation</i> , 2004, 110, 3509-3511.	1.6	20
155	A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor. <i>Country Review Ukraine</i> , 2008, 10, B16-B23.	0.8	20
156	Clinical Characteristics, Vascular Function, and Inflammation in Women With Angina in the Absence of Coronary Atherosclerosis. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 65-73.	2.3	19
157	Upper body fat predicts metabolic syndrome similarly in men and women. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12941.	1.7	18
158	Recent Nutrition Research: Implications for Foods of the Future. <i>Annals of Medicine</i> , 1991, 23, 187-193.	1.5	17
159	Ethnic and Gender Susceptibility to Metabolic Risk. <i>Metabolic Syndrome and Related Disorders</i> , 2014, 12, 110-116.	0.5	17
160	Is There a Gradient of Mortality Risk among Men with Low Cardiorespiratory Fitness?. <i>Medicine and Science in Sports and Exercise</i> , 2015, 47, 1825-1832.	0.2	17
161	Cholesterol Efflux Capacity as a Therapeutic Target. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2211-2213.	1.2	17
162	Current trends in non-HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2019, 13, 563-567.	0.6	17

#	ARTICLE	IF	CITATIONS
163	Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes. BMJ: British Medical Journal, 2007, 334, 982-982.	2.4	16
164	Use of Emerging Lipoprotein Risk Factors in Assessment of Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2012, 307, 2540-2.	3.8	16
165	Influence of Upper and Lower Body Adipose Tissue on Insulin Sensitivity in South Asian Men. Journal of Investigative Medicine, 2012, 60, 999-1004.	0.7	16
166	Dietary Fat: At the Heart of the Matter. Science, 2001, 293, 801d-804.	6.0	16
167	Relationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome. Journal of Investigative Medicine, 2007, 55, 237-247.	0.7	14
168	Plasma noncholesterol sterols as indicators of cholesterol absorption. Journal of Lipid Research, 2013, 54, 873-875.	2.0	14
169	Alternative approaches to cholesterol-lowering therapy. American Journal of Cardiology, 2002, 90, 1135-1138.	0.7	13
170	Cholesterol management in patients with heart disease. Postgraduate Medicine, 1997, 102, 81-90.	0.9	11
171	Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men. Journal of Clinical Lipidology, 2016, 10, 1414-1422.e1.	0.6	11
172	Evaluation of coronary artery calcium screening strategies focused on risk categories: The Dallas Heart Study. American Heart Journal, 2009, 157, 1001-1009.	1.2	10
173	Fatty acid oxidation in normotriglyceridemic men. Journal of Clinical Lipidology, 2016, 10, 283-288.	0.6	10
174	Advances in treatment of dyslipidaemia. Nature Reviews Cardiology, 2016, 13, 74-75.	6.1	10
175	An Analysis of Individual Body Fat Depots and Risk of Developing Cancer. Mayo Clinic Proceedings, 2017, 92, 536-543.	1.4	9
176	Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. Progress in Cardiovascular Diseases, 2021, 68, 2-6.	1.6	9
177	Atherosclerosis imaging for risk assessment and primary prevention of cardiovascular disease. Progress in Cardiovascular Diseases, 2003, 46, 115-121.	1.6	8
178	Advancing drug therapy of the metabolic syndrome. Nature Reviews Drug Discovery, 2009, 8, 341-341.	21.5	8
179	Impaired Hepatic Ketogenesis in Moderately Obese Men With Hypertriglyceridemia. Journal of Investigative Medicine, 2009, 57, 590-594.	0.7	8
180	Cholesterol Management in Older Persons. American Journal of Medicine, 2014, 127, 1140-1141.	0.6	8

#	ARTICLE	IF	CITATIONS
181	Statins for All?. American Journal of Cardiology, 2014, 114, 1443-1446.	0.7	8
182	Elevated apolipoprotein B as a risk-enhancing factor in 2018 cholesterol guidelines. Journal of Clinical Lipidology, 2019, 13, 356-359.	0.6	8
183	Statins: Definitive Translational Research. Molecular Medicine, 2014, 20, S20-S23.	1.9	7
184	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clinic Proceedings, 2021, 96, 2660-2670.	1.4	7
185	Scavenger Receptor B-1 Emerges as Anti-atherogenic Candidate. Cell Metabolism, 2016, 23, 755-757.	7.2	6
186	Chronic kidney disease and statin eligibility. Journal of Clinical Lipidology, 2021, 15, 173-180.	0.6	6
187	Utility of metabolic syndrome as a risk enhancing factor in decision of statin use. Journal of Clinical Lipidology, 2021, 15, 255-265.	0.6	6
188	Comparison of the effects of guanabenz and hydrochlorothiazide on plasma lipids. Clinical Pharmacology and Therapeutics, 1988, 44, 297-302.	2.3	5
189	Cholesterol management in high-risk patients without heart disease. Postgraduate Medicine, 1998, 104, 117-129.	0.9	5
190	Statin Intolerance and Noncompliance: An Empiric Approach. American Journal of Medicine, 2022, 135, 318-323.	0.6	5
191	Metabolic syndrome: Part I. Endocrinology and Metabolism Clinics of North America, 2004, 33, ix-xi.	1.2	5
192	Cholesterol-raising effects of coffee: clues to regulation of cholesterol metabolism. Journal of Internal Medicine, 1995, 238, 475-477.	2.7	4
193	Metabolic Syndrome Phenotype in Very Obese Women. Metabolic Syndrome and Related Disorders, 2007, 5, 3-12.	0.5	4
194	Thyroid mimetic as an option for lowering low-density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 409-410.	3.3	4
195	Metabolic syndrome: part II. Endocrinology and Metabolism Clinics of North America, 2004, 33, xi-xiii.	1.2	4
196	Prevalence and significance of risk enhancing biomarkers in the United States population at intermediate risk for atherosclerotic disease. Journal of Clinical Lipidology, 2022, 16, 66-74.	0.6	4
197	Metabolic syndrome: what is it and how should I treat it?. ACC Current Journal Review, 2003, 12, 37-40.	0.1	3
198	Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?. Current Cardiology Reports, 2012, 14, 692-700.	1.3	3

#	ARTICLE	IF	CITATIONS
199	Temporal decline in non-HDL high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2020, 14, 425-430.	0.6	3
200	Coronary Artery Calcium: Where Do We Stand After Over 3 Decades?. <i>American Journal of Medicine</i> , 2021, 134, 1091-1095.	0.6	3
201	Treatment of diabetic dyslipidaemia. <i>Biochemical Society Transactions</i> , 1989, 17, 56-58.	1.6	2
202	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 760-761.	1.2	2
203	Statin Therapy for Primary Prevention in Women: What is the Role for Coronary Artery Calcium?. <i>Journal of Clinical Lipidology</i> , 2022, , .	0.6	2
204	Drug Therapy in Dyslipidemia. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1990, 50, 63-72.	0.6	1
205	Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study. <i>Current Therapeutic Research</i> , 2006, 67, 321-333.	0.5	1
206	Treating Hypercholesterolemia in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 695.	3.8	1
207	Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. <i>JAMA Cardiology</i> , 2019, 4, 473.	3.0	1
208	Reply to KC Hayes. <i>American Journal of Clinical Nutrition</i> , 1993, 57, 232.	2.2	0
209	Reply to ML Goldberg and MG Enig. <i>American Journal of Clinical Nutrition</i> , 1993, 58, 244.	2.2	0
210	Reply to AM Zivkovic and JB German. <i>American Journal of Clinical Nutrition</i> , 2007, 85, 241-242.	2.2	0
211	Cholesterol Management in the Context of Risk Factor Profile. , 0, , 187-195.		0
212	Perspectives on Cholesterol Guidelines. <i>Contemporary Endocrinology</i> , 2015, , 313-327.	0.3	0
213	Management of Cholesterol Disorders. , 2007, , 2667-2691.		0